Etodolac | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | |
Etodolac | hsa00330 | Arginine and proline metabolism | 4.86E-02 | 1 | P17707 | AMD1 | More | |
Etodolac | hsa00520 | Amino sugar and nucleotide sugar metabolism | 7.87E-03 | 3 | Q16222, Q9Y223, P06865 | UAP1, GNE, HEXA | More | |
Etodolac | hsa00561 | Glycerolipid metabolism | 2.51E-02 | 2 | P51648, P23743 | ALDH3A2, DGKA | More | |
Etodolac | hsa00562 | Inositol phosphate metabolism | 7.30E-04 | 4 | P27987, Q96PE3, P19174, P42338 | ITPKB, INPP4A, PLCG1, PIK3CB | More | |
Etodolac | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | |
Etodolac | hsa00603 | Glycosphingolipid biosynthesis - globo and isoglobo series | 4.30E-03 | 2 | P06865, O75752 | HEXA, B3GALNT1 | More | |
Etodolac | hsa00620 | Pyruvate metabolism | 2.51E-02 | 2 | P40925, P51648 | MDH1, ALDH3A2 | More | |
Etodolac | hsa00630 | Glyoxylate and dicarboxylate metabolism | 2.78E-03 | 2 | P40925, P15104 | MDH1, GLUL | More | |
Etodolac | hsa01100 | Metabolic pathways | 4.12E-02 | 12 | P15104, P51648, P42338, Q96PE3, P19174, P27987, Q13370, P40925, P23743, P43034, P09917, Q53FZ2 | GLUL, ALDH3A2, PIK3CB, INPP4A, PLCG1, ITPKB, PDE3B, MDH1, DGKA, PAFAH1B1, ALOX5, ACSM3 | More | |
Etodolac | hsa01521 | EGFR tyrosine kinase inhibitor resistance | 4.13E-05 | 5 | P49841, Q92529, P19174, P42338, Q9NRA1 | GSK3B, SHC3, PLCG1, PIK3CB, PDGFC | More | |
Etodolac | hsa02010 | ABC transporters | 4.93E-02 | 1 | Q8IZY2 | ABCA7 | More | |
Etodolac | hsa03320 | PPAR signaling pathway | 3.78E-02 | 2 | Q6PCB7, Q9UNU6 | SLC27A1, CYP8B1 | More | |
Etodolac | hsa04012 | ErbB signaling pathway | 9.49E-03 | 3 | Q92529, P19174, P42338 | SHC3, PLCG1, PIK3CB | More | |
Etodolac | hsa04014 | Ras signaling pathway | 2.29E-04 | 7 | P42338, Q92529, Q9NRA1, P49767, P63218, P50151, P19174 | PIK3CB, SHC3, PDGFC, VEGFC, GNG5, GNG10, PLCG1 | More | |
Etodolac | hsa04015 | Rap1 signaling pathway | 3.91E-02 | 4 | Q9NRA1, P49767, P42338, P19174 | PDGFC, VEGFC, PIK3CB, PLCG1 | More | |
Etodolac | hsa04020 | Calcium signaling pathway | 2.43E-03 | 7 | P27987, P19174, P0DP24, P51828, P23634, Q9NRA1, P49767 | ITPKB, PLCG1, CALM2, ADCY7, ATP2B4, PDGFC, VEGFC | More | |
Etodolac | hsa04024 | cAMP signaling pathway | 3.79E-02 | 3 | P51828, P0DP24, P23634 | ADCY7, CALM2, ATP2B4 | More | |
Etodolac | hsa04062 | Chemokine signaling pathway | 4.35E-03 | 6 | P07948, P42338, P19174, Q92529, P63218, P50151 | LYN, PIK3CB, PLCG1, SHC3, GNG5, GNG10 | More | |
Etodolac | hsa04070 | Phosphatidylinositol signaling system | 3.19E-04 | 5 | P19174, P42338, P23743, Q96PE3, P27987 | PLCG1, PIK3CB, DGKA, INPP4A, ITPKB | More | |
Etodolac | hsa04071 | Sphingolipid signaling pathway | 2.14E-02 | 3 | Q13510, Q13362, Q9UQC2 | ASAH1, PPP2R5C, GAB2 | More | |
Etodolac | hsa04072 | Phospholipase D signaling pathway | 1.85E-04 | 6 | P42338, Q92529, P19174, Q14344, P23743, Q9NRA1 | PIK3CB, SHC3, PLCG1, GNA13, DGKA, PDGFC | More | |
Etodolac | hsa04114 | Oocyte meiosis | 1.05E-04 | 9 | Q9Y6D9, P51812, Q02750, P0DP24, P16298, Q17RY0, P51828, P27348, Q13362 | MAD1L1, RPS6KA3, MAP2K1, CALM2, PPP3CB, CPEB4, ADCY7, YWHAQ, PPP2R5C | More | |
Etodolac | hsa04151 | PI3K-Akt signaling pathway | 2.55E-03 | 8 | P42338, Q9NRA1, P49767, P08238, P63218, P50151, O15335, P14784 | PIK3CB, PDGFC, VEGFC, HSP90AB1, GNG5, GNG10, CHAD, IL2RB | More | |
Etodolac | hsa04261 | Adrenergic signaling in cardiomyocytes | 1.06E-02 | 4 | P51828, Q13362, P0DP24, P23634 | ADCY7, PPP2R5C, CALM2, ATP2B4 | More | |
Etodolac | hsa04370 | VEGF signaling pathway | 6.63E-05 | 5 | P19174, P16298, P42338, Q05397, Q02750 | PLCG1, PPP3CB, PIK3CB, PTK2, MAP2K1 | More | |
Etodolac | hsa04371 | Apelin signaling pathway | 1.24E-02 | 4 | P63218, P50151, Q13370, Q14344 | GNG5, GNG10, PDE3B, GNA13 | More | |
Etodolac | hsa04510 | Focal adhesion | 1.55E-02 | 5 | P42338, O15335, Q9NRA1, P49767, Q92529 | PIK3CB, CHAD, PDGFC, VEGFC, SHC3 | More | |
Etodolac | hsa04610 | Complement and coagulation cascades | 2.33E-03 | 1 | P0C0L4 | C4A | More | |
Etodolac | hsa04611 | Platelet activation | 4.11E-02 | 3 | P42338, Q14344, P07948 | PIK3CB, GNA13, LYN | More | |
Etodolac | hsa04650 | Natural killer cell mediated cytotoxicity | 3.08E-02 | 3 | P16298, P50591, Q02750 | PPP3CB, TNFSF10, MAP2K1 | More | |
Etodolac | hsa04658 | Th1 and Th2 cell differentiation | 1.01E-02 | 4 | P07766, P19174, P14784, Q13761 | CD3E, PLCG1, IL2RB, RUNX3 | More | |
Etodolac | hsa04659 | Th17 cell differentiation | 2.16E-02 | 4 | P19174, P14784, P08238, P07766 | PLCG1, IL2RB, HSP90AB1, CD3E | More | |
Etodolac | hsa04662 | B cell receptor signaling pathway | 2.78E-02 | 3 | P42338, P07948, Q8N149 | PIK3CB, LYN, LILRA2 | More | |
Etodolac | hsa04664 | Fc epsilon RI signaling pathway | 7.30E-04 | 4 | P42338, P07948, P19174, P09917 | PIK3CB, LYN, PLCG1, ALOX5 | More | |
Etodolac | hsa04666 | Fc gamma R-mediated phagocytosis | 1.73E-02 | 3 | P07948, P42338, P19174 | LYN, PIK3CB, PLCG1 | More | |
Etodolac | hsa04710 | Circadian rhythm | 1.67E-02 | 2 | Q16526, Q9Y478 | CRY1, PRKAB1 | More | |
Etodolac | hsa04720 | Long-term potentiation | 2.35E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | |
Etodolac | hsa04722 | Neurotrophin signaling pathway | 4.87E-02 | 3 | P42338, P19174, Q92529 | PIK3CB, PLCG1, SHC3 | More | |
Etodolac | hsa04724 | Glutamatergic synapse | 1.73E-02 | 3 | P63218, P50151, P15104 | GNG5, GNG10, GLUL | More | |
Etodolac | hsa04725 | Cholinergic synapse | 1.73E-02 | 3 | P63218, P50151, P42338 | GNG5, GNG10, PIK3CB | More | |
Etodolac | hsa04726 | Serotonergic synapse | 3.41E-02 | 3 | P63218, P50151, P09917 | GNG5, GNG10, ALOX5 | More | |
Etodolac | hsa04727 | GABAergic synapse | 6.57E-03 | 3 | P63218, P50151, P15104 | GNG5, GNG10, GLUL | More | |
Etodolac | hsa04730 | Long-term depression | 1.56E-02 | 2 | Q14344, P07948 | GNA13, LYN | More | |
Etodolac | hsa04910 | Insulin signaling pathway | 4.11E-02 | 3 | Q92529, Q13370, P42338 | SHC3, PDE3B, PIK3CB | More | |
Etodolac | hsa04914 | Progesterone-mediated oocyte maturation | 3.89E-04 | 7 | Q17RY0, P42338, Q13370, Q9Y6D9, P08238, P51812, Q02750 | CPEB4, PIK3CB, PDE3B, MAD1L1, HSP90AB1, RPS6KA3, MAP2K1 | More | |
Etodolac | hsa04915 | Estrogen signaling pathway | 4.76E-03 | 4 | P42338, Q92529, P08238, P11142 | PIK3CB, SHC3, HSP90AB1, HSPA8 | More | |
Etodolac | hsa04916 | Melanogenesis | 2.18E-02 | 2 | P49841, Q01726 | GSK3B, MC1R | More | |
Etodolac | hsa04920 | Adipocytokine signaling pathway | 4.31E-02 | 2 | Q9Y478, Q96RR4 | PRKAB1, CAMKK2 | More | |
Etodolac | hsa04923 | Regulation of lipolysis in adipocytes | 3.64E-02 | 2 | Q13370, P42338 | PDE3B, PIK3CB | More | |
Etodolac | hsa04925 | Aldosterone synthesis and secretion | 1.32E-02 | 3 | P51828, P0DP24, P23634 | ADCY7, CALM2, ATP2B4 | More | |
Etodolac | hsa04926 | Relaxin signaling pathway | 1.31E-03 | 5 | P42338, P63218, P50151, P49767, Q92529 | PIK3CB, GNG5, GNG10, VEGFC, SHC3 | More | |
Etodolac | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 4.11E-02 | 3 | P42338, P49767, P19174 | PIK3CB, VEGFC, PLCG1 | More | |
Etodolac | hsa04935 | Growth hormone synthesis, secretion and action | 2.78E-02 | 3 | P19174, P42338, Q92529 | PLCG1, PIK3CB, SHC3 | More | |
Etodolac | hsa04961 | Endocrine and other factor-regulated calcium reabsorption | 2.09E-02 | 2 | P23634, P62491 | ATP2B4, RAB11A | More | |
Etodolac | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | |
Etodolac | hsa04966 | Collecting duct acid secretion | 4.93E-02 | 1 | P00918 | CA2 | More | |
Etodolac | hsa04970 | Salivary secretion | 3.20E-03 | 3 | P51828, P23634, P0DP24 | ADCY7, ATP2B4, CALM2 | More | |
Etodolac | hsa04972 | Pancreatic secretion | 4.94E-03 | 3 | P23634, P51828, P62491 | ATP2B4, ADCY7, RAB11A | More | |
Etodolac | hsa05032 | Morphine addiction | 2.22E-02 | 3 | P63218, P50151, Q13370 | GNG5, GNG10, PDE3B | More | |
Etodolac | hsa05100 | Bacterial invasion of epithelial cells | 3.64E-02 | 2 | P42338, Q92529 | PIK3CB, SHC3 | More | |
Etodolac | hsa05133 | Pertussis | 4.20E-02 | 1 | P0C0L4 | C4A | More | |
Etodolac | hsa05135 | Yersinia infection | 2.58E-02 | 4 | Q05397, P51812, Q02750, Q96JJ3 | PTK2, RPS6KA3, MAP2K1, ELMO2 | More | |
Etodolac | hsa05143 | African trypanosomiasis | 1.31E-02 | 2 | P69905, P68871 | HBA2, HBB | More | |
Etodolac | hsa05144 | Malaria | 3.09E-02 | 2 | P69905, P68871 | HBA2, HBB | More | |
Etodolac | hsa05162 | Measles | 3.91E-02 | 4 | P14784, P07766, P42338, P11142 | IL2RB, CD3E, PIK3CB, HSPA8 | More | |
Etodolac | hsa05163 | Human cytomegalovirus infection | 1.14E-02 | 5 | P42338, P63218, P50151, Q14344, P30101 | PIK3CB, GNG5, GNG10, GNA13, PDIA3 | More | |
Etodolac | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 1.14E-02 | 5 | P42338, P63218, P50151, P19174, P07948 | PIK3CB, GNG5, GNG10, PLCG1, LYN | More | |
Etodolac | hsa05169 | Epstein-Barr virus infection | 3.34E-02 | 5 | P42338, P07948, P30101, Q13761, P07766 | PIK3CB, LYN, PDIA3, RUNX3, CD3E | More | |
Etodolac | hsa05170 | Human immunodeficiency virus 1 infection | 9.69E-04 | 10 | P42338, Q02750, P62879, P63218, P50151, P16298, Q05397, P30101, P19174, P07766 | PIK3CB, MAP2K1, GNB2, GNG5, GNG10, PPP3CB, PTK2, PDIA3, PLCG1, CD3E | More | |
Etodolac | hsa05200 | Pathways in cancer | 3.05E-02 | 8 | P42338, P08238, P19174, P49767, P63218, P50151, Q14344, P14784 | PIK3CB, HSP90AB1, PLCG1, VEGFC, GNG5, GNG10, GNA13, IL2RB | More | |
Etodolac | hsa05214 | Glioma | 9.49E-03 | 3 | Q92529, P42338, P19174 | SHC3, PIK3CB, PLCG1 | More | |
Etodolac | hsa05215 | Prostate cancer | 4.87E-02 | 3 | Q9NRA1, P08238, P42338 | PDGFC, HSP90AB1, PIK3CB | More | |
Etodolac | hsa05218 | Melanoma | 3.64E-02 | 2 | Q9NRA1, P42338 | PDGFC, PIK3CB | More | |
Etodolac | hsa05231 | Choline metabolism in cancer | 1.17E-03 | 4 | P42338, Q9NRA1, P19174, P23743 | PIK3CB, PDGFC, PLCG1, DGKA | More | |
Etodolac | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.93E-02 | 1 | P54284 | CACNB3 | More | |